OBJECTIVES: To investigate the effects and underlying mechanism of action of naloxone on lipopolysaccharide (LPS)induced activation of retinal microglia in vitro. METHODS: Rat retinal microglia primary cultures were divided into four treatment groups: untreated; 1 µg/ml LPS for 12 h; 0.5, 1.0 or 2.0 µM naloxone for 30 min before LPS; 2.5 or 5.0 µM SB203580 for 12 h before LPS and naloxone. Levels of tumour necrosis factor (TNF)-a and interleukin (IL)-1b were determined by enzyme-linked immuno sorbent assay. Western blot analysis and double immunofluorescence were used to examine activation of the mitogen activated protein kinase (MAPK) signalling pathway. RESULTS: LPS induced an increase in TNF-a and IL-1b in culture supernatants, which was dose-dependently inhibited by naloxone. Naloxone also dose-dependently inhibited LPS-induced increases in phosphorylated p38 MAPK. Pretreatment of cells with SB203580 attenuated the inhibitory effect of naloxone on TNF-a and IL-1b production. CONCLUSIONS: Naloxone suppressed LPSinduced activation of cultured retinal microglia and this suppression appeared to occur partly through the p38 MAPK signalling pathway. Naloxone may have therapeutic potential in neurodegenerative diseases characterized by the activation of microglia.
Introduction
Parkinson's disease, Alzheimer's disease, multiple sclerosis and retinopathies are characterized by neurodegeneration. 1 -3 Research has identified few early interventions that can prevent or slow the course of retinopathic disease. 4 -6 While the pathological mechanisms of neurodegenerative disorders are not fully understood, studies suggest that glial cells increase in number and become activated in early disease, and in post-traumatic brain YF Xu, LL Fu, CH Jiang et al. Naloxone inhibition of LPS-induced activation of retinal microglia injuries and ischaemia. 7 -11 These activated microglial cells, which can release tumour necrosis factor (TNF)-α, interleukin (IL)-1β and other cytokines deleterious to neurons, 12 -17 play important roles in inflammationmediated neurodegeneration and neurotoxicity. 12 -14,18 Microenvironmental changes during the neurodegeneration process can also activate microglia, forming a vicious circle that might be one of the major causes of neuronal death. 7 -10 Inhibition of activated microglia could, theoretically, prevent the onset or delay the development of neurodegeneration, 19 -22 although traditional anti-inflammatory drugs have demonstrated only limited effects in this context. 19 It has been demonstrated that naloxone, a classical opioid receptor antagonist, 23 is capable of inhibiting lipopolysaccharide (LPS)-induced microglia-mediated neurodegeneration, both in vitro and in vivo. 16,24 -29 This may be because naloxone can attenuate the microglial production of nitric oxide and cytokines. 16, 17 Despite evidence suggesting neuroprotective and microglial inhibitory effects of naloxone, the mechanisms by which it mediates these effects are not well understood.
Mitogen activated protein kinases (MAPKs) represent an important and highly conserved family of intracellular signalling molecules that regulate cell function and survival in eukaryotes. 30, 31 There are three well-characterized subfamilies of MAPKs: extracellular signal-regulated kinases (ERKs), which are activated in response to a variety of extracellular stimuli and regulate cell division; c-Jun amino-terminal kinases (JNKs), which control transcription; p38 MAPKs, which regulate the expression of many cytokines and play an important role in activating the immune response. 32, 33 Some studies have suggested that naloxone may have an effect on the p38 MAPK signalling pathway. For example, ultra-low dose naloxone has been shown to restore the antinociceptive effect of morphine in pertussis toxin-treated rats by suppressing p38 MAPK signalling. 34 The present study investigated the effects of naloxone on LPS-induced activation of rat retinal microglia in vitro and explored the involvement of p38 MAPK signalling in the mechanism of action of naloxone in these cells.
Materials and methods

PRIMARY MICROGLIAL CELL CULTURE
Retinas were obtained under aseptic conditions from newborn male Sprague-Dawley rats (aged 0 -2 days, body weight 5.2 -7.2 g; n = 150) (Fudan University, Shanghai, China). After careful removal of vitreous and retinal blood vessels, the retinas were pulverized using microscissors then incubated in calcium/magnesium-free Hank's balanced salt solution containing 0.25 mg/ml trypsin and 0.2 mg/ml ethylenediaminetetra-acetic acid at 37°C for 8 min. Enzyme-treated tissue was dissociated into a single-cell suspension by gentle pipetting, and trypsin was inactivated using Dulbecco's modified Eagle's medium/ nutrient mixture F-12 (DMEM/F-12, 1:1 ratio; Invitrogen, Carlsbad, CA, USA) containing 10% fetal bovine serum (FBS; Hyclone, Logan, UT, USA) and 1% penicillinstreptomycin (Gibco, Gaithersburg, MD, USA) (complete medium). Cells were pelleted by centrifugation at 5.5 g for 5 min, resuspended in complete medium and seeded at a density of 1 × 10 6 cells/ml in 75cm 2 culture flasks (6 -7 ml/flask; Corning, Corning, NY, USA). Cells were cultured at 37°C in a humidified atmosphere containing 5% carbon dioxide in air, and fed every third day. After 2 weeks, the cultures YF Xu, LL Fu, CH Jiang et al.
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were shaken at 100 rpm on an orbital shaker (rotational radius, 2.54 cm) for 1 h and harvested. The detached cells were centrifuged at 5.5 g for 5 min and plated at 1 × 10 6 cells/ml in complete medium in sixwell plates (2 ml of cell suspension/well) for Western blotting, or 24-well plates (1 ml of cell suspension/well) for immunofluorescence or enzyme-linked immunosorbent assay (ELISA). Experiments were performed in standard culture conditions, as described above.
All study procedures were conducted in accordance with the Association for Research in Vision and Ophthalmology Statement for the Use of Animals in Ophthalmic and Visual Research, 35 and approved by the Animal Ethics Committee of the Eye, Ear, Nose and Throat Hospital of Fudan University.
EXPERIMENTAL DESIGN
Microglial cells (in six-and 24-well plates, as described above) were divided into four groups: (i) untreated; (ii) 1 µg/ml LPS (Sigma-Aldrich, St Louis, MO, USA) for 12 h; (iii) 0.5, 1.0 or 2.0 µM naloxone (Sigma-Aldrich) for 30 min before addition of LPS; and (iv) 2.5 or 5.0 µM SB203580 (Sigma-Aldrich) for 12 h before addition of LPS or naloxone. Cultures treated with naloxone or SB203580 were washed three times with DMEM/F-12 for 5 min each wash before the addition of LPS. SB203580 was dissolved in 1 mg/ml dimethylsulphoxide and diluted in 0.01 M phosphate buffered saline (PBS; pH 7.3). LPS and naloxone were diluted in DMEM/F-12. The dose levels of SB203580 were chosen according to a previous study. 36 
IMMUNOFLUORESCENCE
Microglial cells were dissociated from the culture plates, spread on microscope slides and fixed with 4% paraformaldehyde for 10 min. The fixed cells were then washed three times with PBS (10 min each wash) and incubated with blocking solution (1% bovine serum albumin, 0.4% Triton™ X-100, 4% normal goat serum in 0.01 M PBS; pH 7.3) for 20 min at room temperature. Slides were then incubated overnight at 4°C in a mixture of two primary antibodies: mouse antirat OX42 (1 : 200 dilution; Abcam, Cambridge, UK) and rabbit antirat phosphorylated (P)-p38 (1 : 50 dilution; Cell Signaling Technology, Danvers, MA, USA). After washing three times with 0.01 M PBS (pH 7.3; 10 min each wash), the slides were then incubated for 1 h at room temperature in the dark with two secondary antibodies: Alexa Fluor ® 555-conjugated goat antirabbit (1 : 800) and Alexa Fluor ® 488-conjugated goat antimouse (1 : 800; both from Sigma-Aldrich). The slides were then washed three times with PBS (5 min each wash) in the dark, incubated in 300 nM 4′,6-diamidino-2phenylindole (diluted in PBS) for 5 min, and washed three times in PBS in the dark (5 min each wash). Coverslips were mounted with a drop of glycerol and sealed with nail varnish, and the slides were stored at -20°C in darkness. Immunofluorescent staining was visualized using a fluorescence microscope (Nikon, Tokyo, Japan).
TNF-a AND IL-1b ELISA
Supernatants were collected from treated microglial cells for measurement of TNF-α and IL-1β levels by commercial ELISA kits (both from R&D Systems, Minneapolis, MN, USA), according to the manufacturer's instructions. Absorbance at 450 nm was read and cytokine concentrations were extrapolated from a standard curve.
WESTERN BLOTTING
Treated cells (2 × 10 6 cells per protein extraction) were lysed in 0.5 ml sodium dodecyl sulphate (SDS) loading buffer (pH YF Xu, LL Fu, CH Jiang et al. Naloxone inhibition of LPS-induced activation of retinal microglia 6.8 ) and heated at 99°C for 10 min. Total protein (30 µg) was separated by 10% SDSpolyacrylamide gel electrophoresis (SDS-PAGE) at 80 V for 20 min, then 120 V for 1 h. Proteins were electrophoretically transferred to nitrocellulose membranes (0.45 µm; Whatman, Maidstone, UK) at 300 mA for 1 h. The membranes were blocked with 5% skimmed milk in 100 mM Tris-buffered saline with 0.1% Tween (TBST; pH 7.7) for 1 h, then incubated overnight at 4°C with rabbit antirat p38 MAPK, rabbit antirat P-p38 MAPK, rabbit antirat JNK, rabbit antirat P-JNK, rabbit antirat ERK, rabbit antirat P-ERK (Cell Signaling Technology; all 1 : 1000 dilution) or mouse antirat βactin antibodies (GenScript, Piscataway, NJ, USA; 1 : 10 000 dilution). Membranes were washed three times with TBST (5 min each wash) and incubated with goat antirabbit (GenScript; 1 : 3000 dilution) or goat antimouse (Southern Biotech, Birmingham, AL, USA; 1 : 3000 dilution) secondary antibodies for 1 h at room temperature. The membranes were washed three times with TBST (5 min each wash) and protein bands were visualized with ECL Plus™ Western blotting reagent (GE Healthcare Biosciences, Piscataway, NJ, USA), digitized using a Typhoon™ scanner (GE Healthcare Biosciences) and quantified with GE ImageQuant™ TL software, version 7.0 (GE Healthcare Biosciences).
STATISTICAL ANALYSES
All experiments were performed in triplicate and data were presented as mean ± SE. Between-group comparisons were performed using one-way analysis of variance. Data were analysed using Stata ® data analysis and statistical software, version 10.0 (StataCorp, College Station, TX, USA). A Pvalue of < 0.05 was considered to be statistically significant.
Results
Treatment of microglial cells with 1 µg/ml LPS for 12 h resulted in increases in TNF-α and IL-1β concentrations in culture medium ( Figs 1A and 1B, respectively) . The addition of naloxone at 1.0 or 2.0 µM significantly inhibited the LPS-induced production of TNFα and IL-1β (P < 0.01 for all comparisons). The lowest concentration of naloxone (0.5 µM) significantly inhibited IL-1β (P < 0.05), but not TNF-α production.
Western blotting showed that p38 MAPK, JNK and ERK were constitutively present in microglia ( Fig. 2A) . LPS treatment induced a visible increase in the amount of P-p38 MAPK, but p38 MAPK, JNK, P-JNK, ERK and P-ERK appeared unchanged. Pretreatment with naloxone dose-dependently reversed the LPS-induced increase in P-p38 MAPK (P < 0.05, Fig. 2B ). Naloxone had no significant effect on the levels of P-JNK or P-ERK (Fig. 2B) .
Immunofluoresence microscopy showed weak P-p38 MAPK immunostaining in OX42positive microglial cells in untreated cultures (Fig. 3A) . LPS-activation was accompanied by an increase in P-p38 MAPK immunostaining ( 
Discussion
Naloxone suppressed LPS-induced microglial activation and the subsequent release of proinflammatory and neurotoxic factors in the present study, most likely through the p38 MAPK pathway.
Microglia are considered to be the major YF Xu, LL Fu, CH Jiang et al.
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resident immune cells in the central nervous system (CNS) and represent approximately 5 -20% of the total glial cell population. 37 They are particularly sensitive to changes in the microenvironment and are activated by various stimuli. 38 Activated microglia are known to contribute to the neurodegeneration that is characteristic of human CNS diseases such as Parkinson's and Alzheimer's disease, 39, 40 and may also contribute to the retinal damage underlying macular degeneration, retinitis pigmentosa and other retinal diseases. 41, 42 Upon activation, microglia change from a latent state to an active state (characterized by shortened hypertrophied processes), followed by migration to the area of tissue damage where they phagocytose neurons. 42, 43 Activated microglia also secrete various proinflammatory and neurotoxic factors, including TNF-α, IL-1β and reactive oxygen species. 12 -17,39 It has been suggested that inhibition of microglial activation, and the consequent reduction in the release of proinflammatory and neurotoxic factors, may be beneficial to neuron survival under pathological conditions. 44, 45 Naloxone, which is a highly potent, nonselective antagonist of classical opioid receptors, 24 has been found to have neuroprotective potential in vivo and in vitro. 24 -26 Degenerative processes in the central and peripheral nervous systems are retarded by naloxone. 16,27 -29 In the CNS, this effect may be closely related to microglial inhibition and a reduction in the release of pro inflammatory and neurotoxic factors. 24 -26 Naloxone has also been found to slow the progression of retinal lesions in mice with age related macular degeneration. 41 
Microglia can be activated in vitro by a number of agents including LPS, HIV-1 coat protein gp120 and β-amyloid peptides. 46 -50 In the present study, treatment with LPS resulted in activation of microglia accompanied by secretion of TNF-α and IL-1β. LPS-induced changes were dose dependently inhibited by naloxone, suggesting that naloxone may have neuroprotective properties as a result of suppression of microglial activation and inhibition of the release of proinflammatory factors. While the specific underlying mechanism of naloxone in microglia is not fully understood, studies have indicated that it may be independent of classical opioid receptors. 19, 28 Some research has suggested that, at low (fM) concentrations, naloxone may mediate its effect through the nicotinamide adenine dinucleotide 51 The p38 MAPK, which can be activated by micro environmental stresses, regulates a vast array of inflammatory cytokines. 30, 31 There is evidence that p38 MAPK may play an important role in microglia-mediated neuropathic pain 30, 34 and in diabetesinduced retinal inflammation. 52 Inhibition of p38 MAPK may offer a novel treatment for early diabetic retinopathy and other complications of diabetes. Immunofluorescence microscopy for P-p38 MAPK and OX42 (a microglia marker) 10, 53 in the present study demonstrated that LPS-induced activation was well correlated with phosphorylation of p38 MAPK in microglia. Western blotting analysis found that LPS increased P-p38 MAPK levels, and this increase was reversed by naloxone. The present study also showed that SB203580, a selective inhibitor of the p38 MAPK signalling pathway, 36, 54 dose dependently reversed naloxone-mediated inhibition of TNF-α and IL-1β release. Taken together, these findings indicate that the LPS-induced increase in P-p38 MAPK may play an important role in microglial activation and the subsequent increase in TNF-α and IL-1β production, and that naloxone may inhibit these processes partly through the p38 MAPK pathway. Levels of p38 MAPK were unchanged in the presence of naloxone in the current study, suggesting that naloxone may bind to microglial receptors and inhibit the kinases regulating p38 MAPK phosphorylation, such as MAP kinase kinase 30, 55 Activation of microglia and neuronal loss can be observed before any noteworthy clinical symptoms in a number of neurodegenerative CNS and retinal diseases. 18,56 -58 Microglial inhibitors may, therefore, play an important role in the prevention and/or treatment of such diseases. As an antagonist of classical opioid receptors, naloxone is currently used to treat acute alcohol intoxication and acute narcotic analgesic poisoning. The absence of toxic side-effects and its ability to cross the blood-brain barrier, 59 which suggests that it is likely to cross the blood-eye barrier, make naloxone a promising treatment for retinal disorders.
In conclusion, the present study showed that naloxone suppresses LPS-induced activation of retinal microglia in vitro, and that this suppression may occur partly through the p38 MAPK signalling pathway. These data suggest that naloxone may have therapeutic potential in neurodegenerative diseases characterized by the activation of microglia. 
